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Background. Mild to moderate adverse events (AEs) are common after treatment of lymphatic filariasis (LF) and pose a major 
challenge for the global LF elimination program. We studied changes in cytokine levels and filarial worm components in plasma of 
subjects with and without AEs following treatment of LF.
Methods. Participants (n = 24) were hospitalized and monitored for AEs following treatment. Cytokines (27), filarial DNA, 
circulating filarial antigen (CFA), and immune complexes were measured in plasma samples collected before and after treatment.
Results. Levels for 16 cytokines increased after treatment in individuals with moderate AEs compared to individuals with no 
and/or mild AEs. These included 3 major proinflammatory cytokines (interleukin 6, tumor necrosis factor α, and interleukin 1β). 
Eotaxin-1 levels were elevated at baseline in individuals who developed moderate AEs after treatment; thus, eotaxin-1 is a potential 
biomarker for AE risk. CFA and filarial DNA levels increased more in individuals with moderate AEs after treatment than in people 
with no/mild AEs.
Conclusions. Increases in cytokine, filarial DNA, and CFA levels were associated with development of AEs following treatment 
of LF. Improved understanding of the pathogenesis of AEs may lead to improved methods for their prevention or management that 
could increase compliance in elimination programs.
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Lymphatic filariasis (LF) is a neglected tropical disease that 
is caused by the nematode parasites Wuchereria bancrofti, 
Brugia malayi, and Brugia timori. Adult worms release first-
stage larvae (microfilariae [Mf]) into the blood, and these 
are ingested by mosquitoes. The parasites develop to become 
infective third-stage larvae that can initiate new infections 
when they are transmitted to humans by mosquitoes. The 
worms and the host’s inflammatory responses can lead to 
severe morbidity with lymphedema, hydrocele, and elephan-
tiasis [1].
The World Health Organization (WHO) launched the Global 
Program to Eliminate LF (GPELF) in the year 2000 with the goal 
of eliminating LF as a public health problem by 2020. The pri-
mary tool used by GPELF is annual mass drug administration 
(MDA), and some 500 million people are treated each year [2]. 
The medications used—namely, albendazole (ALB), ivermectin 
(IVM), and diethylcarbamazine (DEC)—have well-established 
safety profiles, and serious adverse events (AEs) related to treat-
ment are very rare. However, mild to moderate AEs such as fever 
and headache are common. High MDA compliance is important 
for LF elimination programs [3]. The fear of AEs in communi-
ties receiving MDA reduces compliance [4, 5]. Understanding 
the pathogenesis of AEs is even more urgent at this time, because 
recent studies have shown that a single dose of all 3 LF MDA 
drugs (IVM, DEC and ALB, sometimes called “IDA”) is more 
effective for clearing Mf than the current 2-drug MDA regimens 
[6] (authors’ unpublished observations). This increased efficacy 
may be associated with increased AE rates in infected individuals.
The pathogenesis of AEs after treatment of LF is poorly 
understood. Host immune responses and parasite death are 
believed to be involved, because posttreatment AE rates are 
much higher in infected individuals, and because AE rates are 
correlated with blood Mf counts [7]. AEs are probably related 
to release of parasite antigens and/or Wolbachia (an intracel-
lular alpha proteobacteria found in LF-causing filarial worms). 
Wolbachia-derived molecules may interact directly with the 
innate immune system through ligands such as Toll-like recep-
tors (TLRs) to activate immune cells to release cytokines [8–13]. 
Few studies have looked at changes in cytokines associated with 
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AEs following LF treatment. One study documented increases 
in interleukin (IL) 6 and tumor necrosis factor alpha (TNF-α) 
after treatment in 5 men with AEs [14]. Another study reported 
that AEs were associated with increased levels of IL-6, lipo-
polysaccharide binding protein (LBP), IL-10, and soluble TNF 
receptor [15]. Other studies suggested that AEs may be related 
to circulating immune complexes (CICs) that form when filar-
ial antigens are released by dying parasites [16, 17]. CICs from 
plasma of LF-infected individuals have been shown to be proin-
flammatory when added to granulocytes [18]. A  recent clini-
cal trial provided us with the opportunity to use 21st-century 
methods to revisit the issue of AE pathogenesis.
METHODS
Study Design
Plasma samples used for this study were obtained during a phar-
macokinetic trial conducted in Papua New Guinea in 2013 [6]. 
Twenty-four W. bancrofti–infected individuals were randomized 
to 1 of 2 treatment arms: the standard LF MDA regimen for Papua 
New Guinea (ALB and DEC) or the new IDA triple therapy reg-
imen. The AE assessment protocol was described in a previous 
publication [6]. In brief, objective AEs were assessed (vital signs 
and a brief physical examination) for all study participants at 0, 
4, 8, 12, 24, 48, and 72 hours posttreatment in a hospital setting. 
Subjective AEs were assessed at the same times by asking the par-
ticipants open-ended questions about symptoms that developed 
after treatment. All participants were followed as outpatients and 
examined on day 7. Nineteen of 24 participants (79%) developed 
at least 1 AE, and 7 of these individuals had fever >38°C. Blood 
was collected immediately before treatment and at 11 time-points 
after treatment (1–72 hours). Notable in this study was the high 
Mf levels (geometric mean,  1679 [range, 133–13 776] Mf/mL). 
Plasma samples were stored and shipped at –80°C. Informed con-
sent was obtained from all participants as previously described [6].
Adverse Events Classification
AEs were scored as none, mild, or moderate. Those with mod-
erate AEs (n = 7) had at least 1 new symptom plus objectively 
measured fever (a temperature of ≥38°C) within 72 hours after 
treatment. Individuals with subjective or objective AEs without 
fever were considered to have mild AEs (n = 12). Individuals 
with no objective or subjective symptoms were considered to 
have no AEs (n = 5).
Cytokine Assay
Twenty-seven cytokines were measured using a MAGPIX system 
with the Bio-Plex Human 27-Plex Cytokine Panel and Bio-Plex 
Cytokine Reagent Kit (Bio-Rad, Hercules, California). Plasma 
samples were thawed and centrifuged before testing. A prelimi-
nary study tested samples from all 12 time-points (pretreatment 
and 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours posttreatment) 
for 7 participants. Since there were no changes in cytokine levels 
during the first 6 hours, only 7 time points (pretreatment and 8, 
12, 24, 36, 48, and 72 hours posttreatment) were tested for the 
remaining 17 study participants. All samples were tested in dupli-
cate, and all samples from the same individual were run on the 
same plate. The cytokine assay panel included IL-1β, IL-1Ra, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, 
IL-17, basic fibroblast growth factor (FGF), eotaxin-1, granulo-
cyte colony-stimulating factor (G-CSF), granulocyte macrophage 
colony-stimulating factor (GM-CSF), interferon gamma (IFN-γ), 
interferon gamma-induced protein 10 (IP-10), monocyte chemo-
attractant protein 1 (MCP-1), macrophage inflammatory protein 
(MIP) 1β and 1α, platelet-derived growth factor BB (PDGF-BB), 
regulated on activation, normal T cell expressed and secreted 
(RANTES), TNF-α, and vascular endothelial growth factor 
(VEGF). Standard curves were calculated using the manufactur-
er’s software, and our analysis considered mean concentrations 
(picograms per milliliter) from 2 duplicate wells. Mean levels 
for all 27 cytokines were calculated for each AE group at each 
time-point. Kruskal–Wallis H tests were used to compare abso-
lute cytokine levels between the 3 AE groups at each time-point. 
Wilcoxon signed-rank tests were used to compare posttreatment 
levels to baseline levels within AE groups for each time-point. 
After evaluation of the data, 3 outliers with extremely elevated 
levels at baseline were excluded from the analysis.
Circulating Filarial Antigen
A direct sandwich enzyme immunoassay was performed as pre-
viously described [19, 20]. Plasma samples were available for 
21 of the 24 individuals for this test (6 moderate, 10 mild, and 
5 no AEs), and samples from 5 time-points were tested (pre-
treatment and 6, 12, 24, and 48 hours posttreatment). All sam-
ples from individual participants were tested in duplicate on the 
same plate. The mean circulating filarial antigen (CFA) levels 
were calculated for each AE group at each time-point. Kruskal–
Wallis H tests were used to compare the absolute CFA levels 
between the 3 AE groups at each time-point. Wilcoxon signed-
rank tests were used to compare posttreatment CFA levels at 
each time-point to baseline levels within the AE groups.
Detection of Filarial DNA by Quantitative Polymerase Chain Reaction
DNA was extracted from 100 µL of plasma using the E.Z.N.A. 
Tissue DNA Kit (Omega Bio-tek) using the manufacturer’s 
protocol. The quantitative polymerase chain reaction (qPCR) 
assay was a TaqMan probe-based assay, and the target was the 
“long DNA repeat” of W. bancrofti (GenBank accession number 
AY297458). We used previously published primers and probes 
[21] purchased from Integrated DNA Technologies. Real-time 
PCR reactions were performed with 10 μL of TaqMan master 
mix (Applied Biosystems) plus 450 nmol/L of primers, 125 nmo-
l/L probe, and 2 μL DNA with a final volume of 20 μL. Thermal 
cycling was performed with a QuantStudio 7-Plex Real-Time 
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out for 40 cycles, and cycle threshold (Ct) values were deter-
mined using the manufacturer’s software. Plasma samples were 
available for 21 of the 24 individuals for this assay (7 moderate, 
9 mild, and 5 no AEs), and 7 time-points were selected (pre-
treatment and 8, 12, 24, 36, 48, and 72 hours posttreatment). 
Samples were run in duplicate, and all samples from individ-
ual participants were tested on the same plate. Each plate con-
tained a positive control (DNA extracted from W. bancrofti Mf), 
and 2 negative controls (DNA extracted from plasma samples 
from healthy North American control subjects and deionized 
water). Delta Ct values (baseline Ct value minus posttreatment 
Ct value) were calculated at each time-point for each individual, 
and 1-way analysis of variance analysis was used to compare the 
∆Ct values between the 3 AE groups at each time-point.
Immune Complex Assay
In this assay, CICs were incubated with human C1q (part of 
the first component in the classical complement pathway) that 
was immobilized on microtiter plates. C1q was purchased from 
Sigma-Aldrich. Nunc Immulon 2HB flat-bottom 96-well plates 
(Thermo Scientific) were coated with 50 µL of 0.01 mg/mL C1q 
in 1× phosphate-buffered saline (PBS) pH7.4 and incubated at 
4°C overnight. Plates were washed and blocked for 1 hour at 
room temperature. After washing, 50 µL sample plasma or stan-
dard (diluted 1:60 in PBS with 0.5% casein, 0.5% Tween-20) was 
added to each well, and the plates were incubated at room tem-
perature for 1 hour. Aggregated human γ-globulin (AHG) was 
used as the positive control and standard. Alkaline phospha-
tase-conjugated goat antihuman immunoglobulin G was used at 
a dilution of 1:1000, and plates were incubated for 1 hour at 37°C. 
The plates were developed with alkaline phosphatase substrate 
(pNPP disodium salt hexahydrate) and read at 405 nm. Plasma 
was available from 22 of the 24 individuals for this assay (7 mod-
erate, 10 mild, and 5 no AEs), and 7 time-points were selected 
(pretreatment and 8, 12, 24, 36, 48, and 72 hours posttreatment). 
Samples were run in duplicate and all samples from individual 
participants were run on the same plate. Each plate contained 2 
negative controls (plasma samples from healthy North American 
control subjects and deionized water). Values were expressed as 
nanograms per milliliter of AHG, and mean CIC values were cal-
culated for each AE group at each time-point. Kruskal–Wallis H 
tests were used to compare absolute CIC levels between the 3 AE 
groups at each time-point. Wilcoxon signed-rank tests were used 
to compare posttreatment CIC levels at each time-point to base-
line levels within each AE group.
RESULTS
Cytokine Levels
Three of the 24 individuals (all in the mild AE group) had ex-
tremely elevated cytokine levels at baseline, and they were 
excluded from the analysis. These 3 individuals had outlier lev-
els for 9, 12, and 14 of the 27 measured cytokines respectively, 
at baseline. These high baseline cytokine levels were unrelated 
to treatment and their inclusion would have distorted the data, 
because the aim of the study was to investigate the change in 
cytokines posttreatment.
Changes in cytokine levels after treatment were significantly 
different in persons with moderate AEs compared to those in 
persons with no and/or mild AEs for 22 of the 27 cytokines 
Table 1. Changes in Cytokines at Different Times After Treatment in Persons Who Developed Moderate Adverse Events (AEs) After Treatment of Filariasis 
Compared to Those With No or mild AEs
Hours post 
treatment IL-1β IL-1Ra IL-2 IL-4 IL-6 IL-7 IL-8 IL-10 IL-12 IL-13 IL-15
0 + +
8 ++ ++ + ++ ++ + + ++ -
12 ++ ++ + ++ + + +
24 + - + + + +





IL-17A Eotaxin-1 G-CSF IP-10 MCP-1 MIP-1α PDGF-BB MIP-1β RANTES TNF-α VEGF
0 ++ - -
8 + ++ + + ++ ++ ++ - ++
12 ++ ++ ++ ++ ++ + ++ - +
24 ++ ++ + + - +
36 + + ++ + + +
48 ++ ++ +
72 + +
These differences were due to significant increases (represented with plus signs) in cytokine levels in the moderate AE group compared to the no and/or mild AE groups (Kruskal-Wallis 
analysis followed by post-hoc tests to determine which AE groups were statistically different). IL-2, IL-15 and RANTES were exceptions as these cytokines were decreased (represented with 
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tested (Table 1) (Kruskal–Wallis analysis followed by post hoc 
tests to determine which AE groups were significantly differ-
ent). Most of these cytokines (IL-1β, IL-1Ra, IL-4, IL-6, IL-7, 
IL-10, IL-12, IL-17, G-CSF, IP-10, MCP-1, MIP-1α, PDGF-BB, 
MIP-1β, TNF-α, and VEGF) increased significantly more in the 
moderate AE group after treatment compared to the no and/
or mild AE groups. IL-6, IL-10, MCP-1 and MIP-1β had the 
most dramatic posttreatment increases in the moderate AE 
group (Figure 1). Several cytokines (IL-8, IL-13, and eotaxin-1) 
were significantly higher at baseline in persons who developed 
moderate AEs. Eotaxin-1 was greatly increased pretreatment in 
6 out of the 7 individuals who later developed moderate AEs 
(Figure  2). Baseline eotaxin-1 levels were not correlated with 
baseline Mf counts. The finding that some cytokines were higher 
at baseline in individuals who would go on to develop AEs was 
surprising, and we decided to redo the analysis including the 
3 excluded individuals. There was still a significant difference 
in baseline eotaxin-1 and IL-8 levels between individuals with 
moderate AEs compared with individuals with no and/or mild 
AEs. However, the difference in IL-13 at baseline disappeared 
when the outliers were included.
Values for several cytokines were lower at baseline (RANTES) 
or decreased significantly posttreatment (IL-2 and IL-15) in 
people who developed moderate AEs compared with people 
with no and/or mild AEs. Five cytokines (IL-5, IL-9, basic FGF, 
GM-CSF, and IFN- γ) did not differ by AE group at any time-
point; however, IL-5 did increase posttreatment as previously 
described [22, 23]. We did not correct for multiple compari-
sons, so additional data would be needed to confirm our find-
ings. However, the differences in cytokine levels were dramatic 
between the AE groups, and they persisted over time making 
the results more credible. Based on the standard significance 
level of .05, approximately 3 differences would be expected to 
be significant by chance for 54 tests (27 cytokines measured at 
2 time-points). We found 28 significant differences in cytokines 
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36 48 72
Figure 1. Mean cytokine levels (± standard error [SE]) in the 3 adverse event (AE) groups over time. Interleukin 6 (IL-6) (A), interleukin 10 (IL-10) (B), monocyte chemoat-
tractant protein 1 (MCP-1) (C), and macrophage inflammatory protein 1β (MIP-1β) (D) increased posttreatment in the moderate AE group, whereas there were no significant 
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CFA Levels and Mf Counts
CFA is known to circulate in the blood of LF-infected indi-
viduals, and this antigen is used as a diagnostic marker. The 
detection limit of the CFA enzyme immunoassay assay is 
6.3  ng/mL. CFA was detected in all samples from all study 
subjects. Baseline CFA levels were positively correlated with 
baseline Mf counts (Spearman ρ = 0.66, P = .001), and abso-
lute CFA levels were significantly higher at baseline in the 
individuals who later developed moderate AEs. CFA levels 
were significantly higher in the moderate AE group com-
pared to the no/mild AE groups at all time-points (Figure 3). 
CFA levels increased in all groups after treatment, but the 
difference was only significant at the 48-hour time-point 
(P  =  .048 by Wilcoxon signed-rank test) compared to the 
baseline level in the moderate AE group. There was no dif-
ference in absolute CFA levels between the 2 treatment arms 
at any time-point.
Baseline Mf counts were higher in individuals who developed 
moderate AEs (geometric mean, 4491 Mf/mL vs 1111 Mf/mL in 
the mild AE group and 1351 Mf/mL in the no AEs group), and 
this difference was significant (P = .017 by the Kruskal–Wallis 
test).
Filarial DNA Levels
Thirty-three percent of participants had detectable filar-
ial DNA in plasma collected before treatment. There was no 
correlation between pretreatment Ct values and baseline Mf 
counts (Spearman ρ  =  –0.1). Filarial DNA was detected in 
plasma of all subjects at 8 hours posttreatment. Also, filarial 
DNA levels increased (Ct values decreased) after treatment 
in persons with filarial DNA detected at baseline. DNA levels 
quickly increased for the first 12–24 hours after treatment, 
after which they start to decrease. However, filarial DNA was 
still detectable in plasma in 95% of individuals 72 hours post-
treatment. There was a statistically significant difference in 
∆Ct values between the 3 AE groups at 12 and 24 hours post-
treatment, and this difference was due to significantly higher 
∆Ct values (larger increase in DNA levels) in the moderate AE 
group compared to the mild AE group (Figure 4). A similar 
trend was observed between the moderate and no AE groups, 
but the difference was not statistically significant due to the 
small number of individuals in the no AE group (n = 5). There 
were no significant differences in filarial DNA levels in plasma 
by treatment arm at any time-point.
CIC Levels
CIC were detected in all samples, and the range at baseline was 
108–1312 ng AHG equivalent/mL (median, 417 ng). Baseline 
CIC levels were positively correlated with Mf counts (Spearman 
ρ  =  0.68, P  =  .006). There was no difference in absolute CIC 
levels between the AE groups at any time-point (Supplementary 
Table 1). CIC levels were relatively stable after treatment, and 
there were no consistent patterns as differences included both 
increases and decreases.
DISCUSSION
The aim of this study was to determine the role of host cytokines, 
and filarial components released by parasites after treatment, in 
the development of AEs in LF-infected individuals. This is the 
most detailed study to date of cytokine responses that occur in 
persons with AEs after treatment of LF. We identified 22 cyto-
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Figure 2. Mean eotaxin-1 levels (± standard error) for all 3 adverse event (AE) groups over time. Eotaxin-1 levels were significantly higher at all time-points in the moderate 








niversity in St. Louis user on 30 N
ovem
ber 2019
Adverse Events After Treatment of LF • JID 2018:217 (15 January) • 285
the 3 AE groups. The majority of these cytokines increased 
more posttreatment in persons who developed moderate AEs. 
Our data are consistent with previously published results such 
as increases in IL-6, TNF-α, and IL-10 posttreatment in peo-
ple with AEs [14, 15]. However, we also found that many other 
cytokines increased in participants with moderate AEs.
Plasma levels of filarial DNA and CFA both increased after 
treatment, and posttreatment increases in CFA were much more 
dramatic in people who developed moderate AEs than in those 
with no/mild AEs. Treatment with ALB/DEC and IVM/DEC/
ALB resulted in similar changes in CFA and filarial DNA levels 
after treatment, suggesting that the 2 treatments have similar 
activity against Mf and adult filarial worms in the first days after 
treatment. CFA levels increased slightly later after treatment 
than filarial DNA, but the CFA increases persisted for a longer 
time. This result is consistent with prior reports of increased 
CFA levels 5–7 days posttreatment [24, 25]. Taken together, our 
results suggest that cytokines, filarial DNA, and CFA all may be 
involved in the pathogenesis of AEs. It is likely that the cyto-
kine responses are triggered by molecules that are released from 
dying parasites. However, it is unclear whether cytokine release 
is triggered by phagocytosis of parasite debris or by direct in-
teraction of parasite molecules with ligands on the surface of 
host cells. Compared to filarial DNA and CFA levels, CIC levels 
were stable after treatment, and there was no difference in CIC 
levels between the AE groups at any time-point. These results 
suggest that CIC may not be involved in the pathogenesis of 
moderate AEs.
Cytokine changes have been extensively studied in patients 
with septicemia or after exposure to endotoxin with sequential 
increases in TNF-α, IL-1β, IL-6, IL-1Ra, and IL-10 [26]. The 
cytokine pattern in this study was somewhat similar in that 
TNF-α was the first to increase with a peak at 8 hours post-
treatment. IL-6 had the largest increase (a 13-fold increase in 
the moderate AE group) with a peak at 12 hours. IL-10, which 
increases later after endotoxin exposure, was not delayed in 
this study; it rose by 8 hours and peaked at 12 hours. Increases 
in proinflammatory cytokines may be stimulated by release 
of Wolbachia from dying filarial worms, but additional stud-
ies will have to be conducted to test this hypothesis. Dramatic 
increases in MCP-1 and MIP-1β/1α in persons with moderate 
AEs suggest that monocytes and/or macrophages are involved 
in the pathogenesis of AEs. Both of these cytokines are released 
by macrophages after endotoxin exposure [27], so this finding 
is consistent with the Wolbachia release hypothesis. Although 
Wolbachia do not contain lipopolysaccharide, they do contain 
endotoxin-like lipoproteins that interact with cellular ligands 
TLR2 and TLR6 [9, 11, 13].
Several baseline characteristics are known to be correlated 
with development of AEs after treatment of LF. For example, 
high Mf counts are a known risk factor [7], and our study con-
firmed that this is the case. High CFA levels have not been 
previously identified as a risk factor for AEs, perhaps because 
antigen levels were not measured. However, the association is 
not surprising, because CFA levels are positively correlated with 
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Figure 4. Filarial DNA levels in plasma (expressed as ∆ cycle threshold [Ct] ± 
standard error) after treatment by adverse event (AE) group. Ct values decreased 
after treatment in all 3 AE groups, signifying an increase in filarial DNA levels in 
plasma. Mean ∆Ct values were significantly greater in the moderate AE group com-
pared with the mild AE group at 12 (P = .025) and 24 (P = .020) hours posttreatment 
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Figure 3. Mean W. bancrofti (Wb) circulating filarial antigen (CFA) levels (± stan-
dard error) for each adverse event (AE) group over time. CFA levels were significantly 
higher in the moderate AE group than in the no and mild AE groups. Significance 
(Kruskal–Wallis H test): *P < .05; **P < .01. CFA levels were significantly higher at 
48 hours posttreatment compared with baseline in the moderate AE group (P = .048 
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certain cytokines prior to treatment were at increased risk for 
moderate AEs was not anticipated. This was especially true for 
eotaxin-1, a chemokine secreted by various cells that attracts 
circulating eosinophils to their respective tissue [28]. One po-
tential explanation for this finding is that individuals with high 
levels of eotaxin-1 may have activated eosinophils that are 
poised for attack. These cells rapidly kill parasites that have been 
damaged by anthelmintic drugs, and this may trigger a more 
vigorous proinflammatory response that results in AEs. This 
hypothesis is supported by the finding that eotaxin-1–deficient 
mice have reduced eosinophil responses to TLR2 activation 
and filarial antigen exposure, and the finding that macrophages 
from these mice produce less IL-6 [29]. Additional research will 
be needed to understand the apparent link between eotaxin-1 
and AEs.
Samples from the Papua New Guinea trial were ideal for our 
study because of the high rate of AEs, the detailed clinical infor-
mation available for participants, and the availability of plasma 
at many time-points after treatment. One limitation is that we 
were unable to assess Wolbachia in the plasma samples for tech-
nical reasons. Another limitation is that the correlations we 
observed do not prove causation.
In conclusion, this study has provided additional information 
on changes in plasma cytokine levels and in filarial worm com-
ponents that are associated with moderate AEs after LF treat-
ment. We have also shown that high Mf counts and high levels 
of CFA and eotaxin-1 at baseline are associated with increased 
risk for moderate AEs. Taken together, our results suggest that 
components released from filarial worms interact with the host 
immune system to release proinflammatory cytokines that lead 
to moderate AEs with fever and associated symptoms. More 
work is needed to identify the specific filarial worm components 
that are responsible for this immune activation, but Wolbachia 
endobacteria represent an attractive candidate. However, they 
are unlikely to be the only contributor, because similar AEs 
occur in patients after treatment of loiasis, and Loa loa does not 
contain Wolbachia [30]. Improved understanding of the patho-
genesis of AEs may lead to strategies to prevent or manage AEs 
in ways that increase compliance with MDA, which is essential 
for the success of LF elimination programs.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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